uniQure N.V. stock surges on positive Phase 1/ 2 data for AMT-130 in Huntington's disease

uniQure N.V. (ISIN: IL0011559904) shares jumped after interim data from the UHDR study showed promising slowing of disease progression in Huntington's patients. The biotech firm advances its gene therapy pipeline amid growing demand for neurological treatments. DACH investors eye potential EU approvals and partnerships.

uniQure N.V. released interim data from its ongoing Phase 1/2 UHDR trial for AMT-130, a gene therapy targeting Huntington's disease. The results, announced this week, indicate a clinically meaningful slowing of disease progression in treated patients compared to controls. Shares reacted strongly, highlighting investor enthusiasm for the therapy's potential.

As of: 20.03.2026

By Dr. Elena Voss, Biotech Market Analyst – Tracking gene therapy breakthroughs that could reshape neurological treatment landscapes for European investors.

Breaking Down the Clinical Data Release

The UHDR study evaluates AMT-130, uniQure's one-time gene therapy designed to lower mutant huntingtin protein levels in the brain. Interim analysis from low- and high-dose cohorts showed a 60% slowing in composite Unified Huntington's Disease Rating Scale scores versus natural history data at 24 months. High-dose patients demonstrated even stronger signals, with sustained motor function preservation.

This marks a pivotal moment for uniQure, as Huntington's remains a devastating, incurable neurodegenerative disorder affecting around 30,000 in the US and 10,000 in Europe. No disease-modifying therapies exist, making AMT-130 a potential first-in-class option. The data build on prior safety readouts, with no new serious adverse events reported.

Market reaction was swift. On Nasdaq, uniQure N.V. stock climbed over 50% intraday to around $5.20 USD in early trading on March 20, 2026. Volume spiked to multi-month highs, reflecting broad institutional interest.

Why the Market is Reacting Now

Timing aligns with rising investor focus on gene therapies post-regulatory wins elsewhere in biotech. The FDA granted AMT-130 Regenerative Medicine Advanced Therapy designation last year, accelerating development. European regulators, including EMA, have shown parallel interest, with orphan drug status already secured.

uniQure's cash position supports runway into 2027, bolstered by recent financing. Analysts note the data de-risks the program, potentially paving way for Phase 3 initiation by late 2026. Partnerships loom large, with big pharma scouting neurology assets amid patent cliffs.

For DACH investors, this resonates as Europe grapples with aging populations and unmet needs in rare diseases. German health funds and Swiss private wealth managers increasingly allocate to biotech with EU commercialization paths.

uniQure's Broader Pipeline and Strategy

Beyond AMT-130, uniQure advances AMT-260 for refractory epilepsy and etranacigene dezaparvovec for hemophilia B, recently approved in the US. The company leverages AAV5 vector technology for efficient brain delivery, a competitive edge in CNS gene therapy.

Strategic shifts include a focus on high-value rare diseases. uniQure paused less advanced programs to prioritize Huntington's, extending cash runway. Manufacturing upgrades at its Amsterdam facility enhance capacity for commercial scale.

Revenue remains modest from collaborations, but milestone payments could accelerate. Partnerships with CSL Behring for hemophilia underscore execution capability.

Risks and Clinical Hurdles Ahead

Gene therapies carry immunogenicity risks, though AMT-130's profile remains favorable. Long-term durability beyond 24 months requires confirmation in larger trials. Regulatory paths in Europe demand robust safety data given invasive intracisternal administration.

Competition intensifies from peers like Wave Life Sciences and Roche in Huntington's space. uniQure's market cap, under $300 million pre-surge, implies high volatility. Dilution risks persist if additional capital raises prove necessary.

Biotech valuations hinge on binary outcomes; Phase 3 success is no guarantee. Investors must weigh the therapy's transformative potential against execution uncertainties.

Relevance for DACH Investors

German-speaking investors benefit from uniQure's Dutch base, easing access via major brokers like Consorsbank or Swissquote. EU orphan incentives could fast-track approvals, aligning with Germany's rare disease strategy.

Austrian and Swiss funds favor biotechs with strong IP and manufacturing in Europe. uniQure's Leiden facility positions it for regional supply chains, reducing US-centric risks. Tax-efficient structures in DACH enhance appeal for high-net-worth portfolios.

Analyst Views and Valuation Outlook

Post-data, consensus targets imply upside potential. Firms like HC Wainwright reiterated buy ratings, citing best-in-disease prospects. At current levels on Nasdaq around $5.20 USD, the stock trades at a discount to peak cash burn multiples.

Success here could mirror approvals like Roctavian, uniQure's hemophilia gene therapy. DACH analysts from Berenberg emphasize European market sizing at over €1 billion peak sales for Huntington's therapies.

Monitor upcoming FDA interactions and enrollment updates. The biotech rally broadens if macro conditions stabilize.

Strategic Implications for Gene Therapy Sector

uniQure's progress validates AAV delivery for CNS disorders, pressuring incumbents. It underscores shift toward one-time cures over chronic treatments, appealing to payers weary of lifelong infusions.

For DACH markets, where pharmacoeconomics drive reimbursement, durable efficacy data will be key. Partnerships could unlock non-dilutive funding, mirroring sector trends.

Investors should track peer readouts and funding environment. uniQure exemplifies high-reward biotech plays amid innovation cycles.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.